Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03TYI
|
|||
| Former ID |
DAP000613
|
|||
| Drug Name |
Aminophylline
|
|||
| Synonyms |
Aminocardol; Aminodur; Aminofilina; Aminofillina; Aminophyllin; Ammophyllin; Cardiofilina; Cardiomin; Cardophylin; Cardophyllin; Carena; Cariomin; DOBO; Diaphilline; Diaphyllin; Diaphylline; Diophllin; Diophyllin; Diuxanthine; Ethophylline; Eufilina; Euphyllin; Euphylline; Euphyllinum; Eurphyllin; Euufilin; Euufillin; Genophyllin; Grifomin; Inophylline; Lasodex; Linampheta; Lixaminol; Metaphyllin; Metaphylline; Minaphil; Miofilin; Neophyiline; Norofilina; Peterphyllin; Phylcardin; Phyllindon; Phyllocontin; Phyllotemp; Somophyllin; Stenovasan; Syntophyllin; Theodrox; Theolamine; Theolone; Theomin; Theophyldine; Thephyldine; Truphylline; Vasofilina; A 1755; BY 108; Minomal(TN); Phyllocontin (TN); TH/100; Truphylline (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bronchial asthma [ICD-11: CA23; ICD-10: J45.9; ICD-9: 493] | Approved | [1] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [2] | ||
| Therapeutic Class |
Bronchodilator Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C16H24N10O4
|
|||
| Canonical SMILES |
CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
|
|||
| InChI |
1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
|
|||
| InChIKey |
FQPFAHBPWDRTLU-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 317-34-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:2659
|
|||
| ADReCS Drug ID | BADD_D00112 ; BADD_D00113 | |||
| SuperDrug ATC ID |
R03DA05
|
|||
| SuperDrug CAS ID |
cas=000314352
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 3A (PDE3A) | Target Info | Inhibitor | [3], [4] |
| KEGG Pathway | Purine metabolism | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 081142. | |||
| REF 2 | Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. | |||
| REF 3 | Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3. | |||
| REF 4 | Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Acta Anaesthesiol Scand. 2002 Mar;46(3):297-302. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.